Moving toward disease modification in polycythemia vera

[Manouche]

« In this article, we provide an overview of the current and evolving treatment landscape of PV and outline our vision for a patient-centered, phlebotomy-free, treatment approach using time-limited, disease-modifying treatment modalities early in the disease course, which could ultimately affect the natural history of the disease. »

 »Additionally, emerging data suggest that early treatment is associated with higher rates of molecular responses, which might eventually enable time-limited therapy. Nonetheless, longer follow-up is needed to assess whether molecular responses associate with clinically meaningful outcome measures such as thrombosis and progression to myelofibrosis or AML »

sciencedirect.com/science/a...

[ainslie]

that’s a pretty good well balanced paper by credible haems, although I note Rux didn’t get much of a mention, I know Mascarenhas is quite pro Rux

[Bluetop]

Thanks, a useful review

[STK52]

thanks. Would love to know timeline for readout

[PhysAssist]

Hi Manouche,

Thanks for the article- I hadn't seen it prior to your posting it.

Best,

PA

Also, it led me to this:

sanger.ac.uk/science/tools/...

Which is a very interesting calculator- of investigational import only, at least so far...

...and this:

Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management

onlinelibrary.wiley.com/doi...